

# Javier Martin-Broto

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1125258/publications.pdf>

Version: 2024-02-01

148  
papers

9,696  
citations

44042

48  
h-index

40954

93  
g-index

151  
all docs

151  
docs citations

151  
times ranked

8704  
citing authors

#	ARTICLE	IF	CITATIONS
1	Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv51-iv67.	0.6	641
2	Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer. <i>New England Journal of Medicine</i> , 2009, 361, 766-776.	13.9	448
3	Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. <i>Lancet Oncology</i> , The, 2009, 10, 1045-1052.	5.1	430
4	Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv68-iv78.	0.6	413
5	Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up†. <i>Annals of Oncology</i> , 2021, 32, 1348-1365.	0.6	381
6	Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv79-iv95.	0.6	380
7	Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-ST5 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. <i>Lancet Oncology</i> , The, 2017, 18, 812-822.	5.1	370
8	Building a global consensus approach to chordoma: a position paper from the medical and patient community. <i>Lancet Oncology</i> , The, 2015, 16, e71-e83.	5.1	367
9	Deletions Affecting Codons 557-558 of the c-KIT Gene Indicate a Poor Prognosis in Patients With Completely Resected Gastrointestinal Stromal Tumors: A Study by the Spanish Group for Sarcoma Research (GEIS). <i>Journal of Clinical Oncology</i> , 2005, 23, 6190-6198.	0.8	336
10	An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma Patients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). <i>Annals of Oncology</i> , 2017, 28, 2399-2408.	0.6	274
11	Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. <i>Lancet</i> , The, 2019, 394, 478-487.	6.3	273
12	Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 2528-2533.	0.8	249
13	Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era. <i>Clinical Cancer Research</i> , 2012, 18, 4458-4464.	3.2	194
14	Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1266.	3.8	190
15	Incorporating the Patient Voice in Sarcoma Research: How Can We Assess Health-Related Quality of Life in This Heterogeneous Group of Patients? A Study Protocol. <i>Cancers</i> , 2021, 13, 1.	1.7	189
16	Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2012, 23, vii49-vii55.	0.6	174
17	Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group. <i>Annals of Oncology</i> , 2017, 28, 1230-1242.	0.6	168
18	Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. <i>Modern Pathology</i> , 2008, 21, 476-484.	2.9	165

#	ARTICLE	IF	CITATIONS
19	Short, Full-Dose Adjuvant Chemotherapy in High-Risk Adult Soft Tissue Sarcomas: A Randomized Clinical Trial From the Italian Sarcoma Group and the Spanish Sarcoma Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 850-856.	0.8	156
20	Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. <i>Journal of Clinical Oncology</i> , 2015, 33, 4276-4283.	0.8	148
21	Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. <i>Journal of Clinical Oncology</i> , 2020, 38, 2178-2186.	0.8	145
22	GEIS guidelines for gastrointestinal sarcomas (GIST). <i>Cancer Treatment Reviews</i> , 2017, 55, 107-119.	3.4	114
23	Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. <i>Annals of Oncology</i> , 2020, 31, 1506-1517.	0.6	103
24	Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 134-144.	5.1	97
25	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , 2021, 127, 2934-2942.	2.0	96
26	A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma. <i>Cancer</i> , 2005, 104, 1706-1712.	2.0	93
27	Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. <i>Annals of Oncology</i> , 2016, 27, 2283-2288.	0.6	90
28	Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. <i>Cancer</i> , 2020, 126, 2637-2647.	2.0	86
29	Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. <i>Cancer</i> , 2012, 118, 5857-5866.	2.0	85
30	Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial. , 2020, 8, e001561.		85
31	Giant cell tumour of bone: new treatments in development. <i>Clinical and Translational Oncology</i> , 2015, 17, 419-430.	1.2	77
32	Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. <i>Annals of Oncology</i> , 2013, 24, 817-823.	0.6	69
33	Adjuvant therapy in primary GIST: state-of-the-art. <i>Annals of Oncology</i> , 2012, 23, 2776-2781.	0.6	67
34	Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2012, 23, vii100-vii109.	0.6	65
35	Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. <i>ESMO Open</i> , 2021, 6, 100170.	2.0	65
36	Efficacy of Sequential High-Dose Doxorubicin and Ifosfamide Compared With Standard-Dose Doxorubicin in Patients With Advanced Soft Tissue Sarcoma: An Open-Label Randomized Phase II Study of the Spanish Group for Research on Sarcomas. <i>Journal of Clinical Oncology</i> , 2009, 27, 1893-1898.	0.8	64

#	ARTICLE	IF	CITATIONS
37	Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study. <i>Annals of Oncology</i> , 2010, 21, 1552-1557.	0.6	64
38	Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery. <i>European Journal of Cancer</i> , 2015, 51, 1611-1617.	1.3	63
39	Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma. <i>JAMA Oncology</i> , 2018, 4, e180219.	3.4	63
40	Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. <i>Oncologist</i> , 2018, 23, 62-70.	1.9	62
41	Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2294-2302.	0.8	61
42	A Comprehensive Review on Solitary Fibrous Tumor: New Insights for New Horizons. <i>Cancers</i> , 2021, 13, 2913.	1.7	60
43	Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas Randomized Clinical Trial: Three Versus Five Cycles of Full-Dose Epirubicin Plus Ifosfamide. <i>Journal of Clinical Oncology</i> , 2015, 33, 3628-3634.	0.8	59
44	Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS). <i>Annals of Oncology</i> , 1998, 9, 871-876.	0.6	57
45	Effects of denosumab on pain and analgesic use in giant cell tumor of bone: Interim results from a phase II study. <i>Acta Oncológica</i> , 2014, 53, 1173-1179.	0.8	57
46	Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1252-1262.	5.1	57
47	International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours “EURO EWING 2012 Protocol. <i>Trials</i> , 2020, 21, 96.	0.7	56
48	Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 456-466.	5.1	51
49	Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study. <i>Sarcoma</i> , 2012, 2012, 1-11.	0.7	50
50	High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial. <i>European Journal of Cancer</i> , 2018, 93, 28-36.	1.3	49
51	Trabectedin and Radiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups. <i>EClinicalMedicine</i> , 2019, 9, 35-43.	3.2	49
52	Role of Surgery in Patients with Recurrent, Metastatic, or Unresectable Locally Advanced Gastrointestinal Stromal Tumors Sensitive to Imatinib: A Retrospective Analysis of the Spanish Group for Research on Sarcoma (GEIS). <i>Annals of Surgical Oncology</i> , 2015, 22, 2948-2957.	0.7	47
53	Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS). <i>Annals of Oncology</i> , 2017, 28, 2994-2999.	0.6	45
54	Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS). <i>Oncologist</i> , 2019, 24, e338-e346.	1.9	44

#	ARTICLE	IF	CITATIONS
55	GEIS 2013 guidelines for gastrointestinal sarcomas (GIST). <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 883-898.	1.1	42
56	Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS). <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 133-146.	1.1	40
57	Nilotinib Counteracts P-Glycoprotein-Mediated Multidrug Resistance and Synergizes the Antitumoral Effect of Doxorubicin in Soft Tissue Sarcomas. <i>PLoS ONE</i> , 2012, 7, e37735.	1.1	38
58	Options for treating different soft tissue sarcoma subtypes. <i>Future Oncology</i> , 2018, 14, 25-49.	1.1	35
59	SEOM Clinical Guideline of management of soft-tissue sarcoma (2016). <i>Clinical and Translational Oncology</i> , 2016, 18, 1213-1220.	1.2	34
60	Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS). <i>Annals of Oncology</i> , 2021, 32, 533-541.	0.6	34
61	Anal canal duplication: a retrospective analysis of 12 cases from two European pediatric surgical departments. <i>Pediatric Surgery International</i> , 2006, 22, 967-973.	0.6	33
62	Clinical implications of KIT and PDGFRA genotyping in GIST. <i>Clinical and Translational Oncology</i> , 2010, 12, 670-676.	1.2	33
63	Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib. <i>British Journal of Cancer</i> , 2017, 117, 1278-1285.	2.9	33
64	Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas. <i>JAMA Oncology</i> , 2020, 6, 535.	3.4	33
65	Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM). <i>Journal of Neuro-Oncology</i> , 2004, 70, 359-370.	1.4	32
66	Adjuvant treatment of GIST with imatinib: Solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS). <i>European Journal of Cancer</i> , 2009, 45, 1103-1106.	1.3	31
67	Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors. <i>BMC Cancer</i> , 2020, 20, 99.	1.1	31
68	MRP1 Overexpression Determines Poor Prognosis in Prospectively Treated Patients with Localized High-Risk Soft Tissue Sarcoma of Limbs and Trunk Wall: An ISG/GEIS Study. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 249-259.	1.9	30
69	Malignant bone tumors (other than Ewing's sarcomas): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS). <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1113-1131.	1.1	30
70	Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib. <i>JAMA Surgery</i> , 2020, 155, e200397.	2.2	29
71	Complete pathological response to neoadjuvant treatment is associated with better survival outcomes in patients with soft tissue sarcoma: Results of a retrospective multicenter study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2166-2172.	0.5	29
72	Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX®/Doxil®) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS). <i>Sarcoma</i> , 2005, 9, 127-132.	0.7	27

#	ARTICLE	IF	CITATIONS
73	Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion. <i>Oncologist</i> , 2015, 20, 823-830.	1.9	26
74	Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study. <i>Oncologist</i> , 2019, 24, e536-e541.	1.9	26
75	Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas. <i>Clinical Cancer Research</i> , 2020, 26, 5801-5808.	3.2	26
76	SEOM Clinical Guideline of management of soft-tissue sarcoma (2020). <i>Clinical and Translational Oncology</i> , 2021, 23, 922-930.	1.2	26
77	Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. <i>Cancer Medicine</i> , 2021, 10, 2645-2659.	1.3	23
78	Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1). <i>Oncotarget</i> , 2016, 7, 67033-67046.	0.8	23
79	Oleanolic and maslinic acid sensitize soft tissue sarcoma cells to doxorubicin by inhibiting the multidrug resistance protein MRP-1, but not P-glycoprotein. <i>Journal of Nutritional Biochemistry</i> , 2014, 25, 429-438.	1.9	22
80	Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial. <i>Clinical Cancer Research</i> , 2021, 27, 3861-3866.	3.2	22
81	Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma. <i>Clinical Cancer Research</i> , 2018, 24, 5239-5249.	3.2	21
82	RG7112, a Small-Molecule Inhibitor of MDM2, Enhances Trabectedin Response in Soft Tissue Sarcomas. <i>Cancer Investigation</i> , 2015, 33, 440-450.	0.6	20
83	Yondelis® (ET-743, Trabectedin) sensitizes cancer cell lines to CD95-mediated cell death: New molecular insight into the mechanism of action. <i>European Journal of Pharmacology</i> , 2011, 658, 57-64.	1.7	18
84	SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016). <i>Clinical and Translational Oncology</i> , 2016, 18, 1221-1228.	1.2	18
85	Gastrointestinal stromal tumors (GISTs): SEAPâ€“SEOM consensus on pathologic and molecular diagnosis. <i>Clinical and Translational Oncology</i> , 2017, 19, 536-545.	1.2	18
86	Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. <i>Clinical Cancer Research</i> , 2022, 28, 1672-1679.	3.2	18
87	sarcoma Full-dose neoadjuvant anthracycline + ifosfamide chemotherapy is associated with a relapse free survival (RFS) and overall survival (OS) benefit in localized high-risk adult soft tissue sarcomas (STS) of the extremities and trunk wall: Interim analysis of a prospective randomized trial. <i>Annals of Oncology</i> , 2016, 27, vi587.	0.6	17
88	GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS). <i>British Journal of Cancer</i> , 2017, 117, 767-774.	2.9	17
89	Disruption of TCF/Î²-Catenin Binding Impairs Wnt Signaling and Induces Apoptosis in Soft Tissue Sarcoma Cells. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1166-1176.	1.9	16
90	New drugs in gastrointestinal stromal tumors. <i>Current Opinion in Oncology</i> , 2020, 32, 314-320.	1.1	16



#	ARTICLE	IF	CITATIONS
91	Sunitinib Exerts In Vitro Immunomodulatory Activity on Sarcomas via Dendritic Cells and Synergizes With PD-1 Blockade. <i>Frontiers in Immunology</i> , 2021, 12, 577766.	2.2	16
92	Impact of Wnt/ $\beta$ -Catenin Inhibition on Cell Proliferation through CDC25A Downregulation in Soft Tissue Sarcomas. <i>Cancers</i> , 2020, 12, 2556.	1.7	15
93	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2479-2490.	0.8	15
94	SEOM clinical guidelines for the management of adult soft tissue sarcomas. <i>Clinical and Translational Oncology</i> , 2012, 14, 541-544.	1.2	14
95	Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study. <i>Investigational New Drugs</i> , 2018, 36, 468-475.	1.2	14
96	Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center. <i>Cancers</i> , 2020, 12, 3740.	1.7	14
97	Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2021, 92, 493-499.	1.2	13
98	The importance of treating by histological subtype in advanced soft tissue sarcoma. <i>Future Oncology</i> , 2017, 13, 23-31.	1.1	12
99	Cancer Stem Cells in Soft-Tissue Sarcomas. <i>Cells</i> , 2020, 9, 1449.	1.8	11
100	Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. <i>ESMO Open</i> , 2020, 5, e000604.	2.0	11
101	Down-Regulation of AKT Signalling by Ursolic Acid Induces Intrinsic Apoptosis and Sensitization to Doxorubicin in Soft Tissue Sarcoma. <i>PLoS ONE</i> , 2016, 11, e0155946.	1.1	11
102	A phase II study of vinorelbine and estramustine in patients with hormone-resistant prostate cancer. <i>Clinical and Translational Oncology</i> , 2005, 7, 66-73.	1.2	10
103	Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study. <i>Investigational New Drugs</i> , 2014, 32, 287-294.	1.2	10
104	Trabectedin clinical cases: use according to indication in diverse clinical scenarios. <i>Future Oncology</i> , 2015, 11, 15-24.	1.1	10
105	A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin. <i>Molecular Oncology</i> , 2021, 15, 3691-3705.	2.1	10
106	Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. <i>Future Oncology</i> , 2021, 17, 2923-2939.	1.1	10
107	Prognostic value of serum CA125 levels in diffuse large B-cell lymphoma: potential role of a new sex- and age-adjusted reference value. <i>International Journal of Laboratory Hematology</i> , 2010, 32, 582-589.	0.7	9
108	Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 132-141.	1.9	9

#	ARTICLE	IF	CITATIONS
109	Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study. Targeted Oncology, 2018, 13, 81-87.	1.7	8
110	Sarcoma stratification by combined pH2AX and MAP17 (PDZK1IP1) levels for a better outcome on doxorubicin plus olaparib treatment. Signal Transduction and Targeted Therapy, 2020, 5, 195.	7.1	8
111	Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma. Expert Review of Anticancer Therapy, 2020, 20, 957-963.	1.1	8
112	Frequency and Characteristics of Familial Melanoma in Spain: The FAM-GEM-1 Study. PLoS ONE, 2015, 10, e0124239.	1.1	8
113	Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study of the Spanish Group for Research on Sarcomas (GEIS). Sarcoma, 2006, 2006, 1-8.	0.7	7
114	Prognostic Impact of let-7e MicroRNA and Its Target Genes in Localized High-Risk Intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study. Cancers, 2020, 12, 2979.	1.7	7
115	Strategies for care of patients with gastrointestinal stromal tumor or soft tissue sarcoma during COVID-19 pandemic: A guide for surgical oncologists. Journal of Surgical Oncology, 2021, 123, 12-23.	0.8	7
116	A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study. Cancers, 2021, 13, 792.	1.7	7
117	Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations. Spanish Group for Sarcoma research (GEIS "GROUP). Part II. Cancer Treatment Reviews, 2021, 99, 102260.	3.4	7
118	WNT/ $\beta$ -Catenin Pathway in Soft Tissue Sarcomas: New Therapeutic Opportunities?. Cancers, 2021, 13, 5521.	1.7	7
119	Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic. Oncologist, 2020, 25, e1562-e1573.	1.9	6
120	CUL4A, ERCC5, and ERCC1 as Predictive Factors for Trabectedin Efficacy in Advanced Soft Tissue Sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) Study. Cancers, 2020, 12, 1128.	1.7	6
121	Different approaches to advanced soft tissue sarcomas depending on treatment line, goal of therapy and histological subtype. Expert Review of Anticancer Therapy, 2020, 20, 15-28.	1.1	6
122	Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS "GROUP). Part I. Cancer Treatment Reviews, 2021, 99, 102259.	3.4	6
123	SEOM guidelines for gastrointestinal stromal sarcomas (GIST). Clinical and Translational Oncology, 2012, 14, 536-540.	1.2	5
124	Targeted treatments of sarcomas and connective tumors beside gastrointestinal stromal tumor. Current Opinion in Oncology, 2016, 28, 338-344.	1.1	5
125	Activity of doxorubicin after high-dose ifosfamide in adult patients with advanced soft tissue sarcoma: A study of the Spanish Group for Research on Sarcomas (GEIS). Annals of Oncology, 1998, 9, 783-785.	0.6	4
126	Review of past and present clinical cases with a view to future treatment options. Future Oncology, 2017, 13, 11-28.	1.1	4



#	ARTICLE	IF	CITATIONS
127	Optimization of the Therapeutic Approach to Patients with Sarcoma: Delphi Consensus. Sarcoma, 2019, 2019, 1-14.	0.7	4
128	A Novel NFIX-STAT6 Gene Fusion in Solitary Fibrous Tumor: A Case Report. International Journal of Molecular Sciences, 2021, 22, 7514.	1.8	4
129	Report from the 4th European Bone Sarcoma Networking meeting: focus on osteosarcoma. Clinical Sarcoma Research, 2018, 8, .	2.3	3
130	Which goals should we pursue in each line of treatment for advanced soft tissue sarcoma?. Future Oncology, 2019, 15, 17-23.	1.1	3
131	Risk-based treatment of non-rhabdomyosarcoma soft-tissue sarcoma in children. Lancet Oncology, The, 2020, 21, 16-17.	5.1	3
132	What is the standard indication of adjuvant or neoadjuvant chemotherapy in localized soft-tissue sarcoma?. Current Opinion in Oncology, 2021, 33, 329-335.	1.1	3
133	The paediatric cancer clinical research landscape in Spain: a 13-year multicentre experience of the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP). Clinical and Translational Oncology, 2021, 23, 2489-2496.	1.2	3
134	A randomized, placebo-controlled, phase 2 trial of INBRX-109 in unresectable or metastatic conventional chondrosarcoma.. Journal of Clinical Oncology, 2022, 40, TPS11582-TPS11582.	0.8	3
135	Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study. British Journal of Cancer, 2006, 94, 1797-1802.	2.9	2
136	Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. European Journal of Surgical Oncology, 2021, 47, 2173-2181.	0.5	2
137	Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STs 1001 Randomized Phase III Trial. Molecular Cancer Therapeutics, 2021, 20, 2539-2552.	1.9	2
138	Current and future systemic treatment options for advanced soft-tissue sarcoma beyond anthracyclines and ifosfamide. Cancer Translational Medicine, 2017, 3, 20.	0.2	2
139	Indirect comparisons in cost-effectiveness analysis: are we being naïve?. Clinical and Translational Oncology, 2015, 17, 85-86.	1.2	1
140	Phase II, singlearm, nonrandomized, and multicenter clinical trial of regorafenib (REG) as a single agent in the firstline setting for patients with metastatic and/or unresectable KIT/PDGFR wild-type GIST. A GEIS and ISG study. Annals of Oncology, 2016, 27, vi492.	0.6	1
141	Phosphorylated-insulin growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study. Clinical Sarcoma Research, 2016, 6, 10.	2.3	1
142	Pazopanib in the treatment of advanced solitary fibrous tumour “ Authors' reply. Lancet Oncology, The, 2019, 20, e128.	5.1	1
143	Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients. Oncotarget, 2018, 9, 17576-17588.	0.8	1
144	Rare solid and cystic presentation of hemangiopericytoma/ solitary fibrous tumor: A case report. Current Problems in Cancer Case Reports, 2022, 6, 100149.	0.1	1

#	ARTICLE	IF	CITATIONS
145	Tumores del estroma gastrointestinal: breve actualización y consenso de la SEAP-SEOM sobre diagnóstico patológico y molecular. Revista Española De Patología, 2017, 50, 89-99.	0.6	0
146	In Reply. Oncologist, 2019, 24, e401-e402.	1.9	0
147	Olaratumab-induced Biomarker Modulation in Sarcomas Response. Molecular Cancer Therapeutics, 2021, 20, 2094-2094.	1.9	0
148	Abstract CT009: A Phase Ib study assessing biomarker modulation in soft tissue sarcoma patients treated with olaratumab followed by olaratumab plus doxorubicin. , 2019, , .		0